Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Lausanne Hospitals
Patient with primary or relapsing prostate cancer for whom F-18-FCH PET/CT is indicated will be proposed to participate to the present study. After signing the patient informed consent, both F-18-FCH and Ga-68-NODAGA-MJ9 PET/CT will be scheduled with a maximum 10 day-interval.
No adverse events are expected.
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Age : adult patients
Karnofsky : ≥ 80%
Patients with histologically proven prostate cancer for whom 18F-fluocholine PET/CT is indicated for primary cancer staging, or for recurrence with increase of blood PSA. In order to provide a detection probability of 30% or more, a blood PSA 0.5 ng / ml or more in post initial curative intent surgery will be required.
Signed informed consent.
You may not be if
Lack of discernment to sign the consent form
Age \<18 years
Patient under hormonal treatment
Clareo Health | Ga-68-NODAGA-MJ9 Compared to F-18-FCH PET/CT for Prostate Cancer Patients
